355 related articles for article (PubMed ID: 29784675)
21. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.
Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055
[TBL] [Abstract][Full Text] [Related]
22. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
Yin L; Xue J; Li R; Zhou L; Deng L; Chen L; Zhang Y; Li Y; Zhang X; Xiu W; Tong R; Gong Y; Huang M; Xu Y; Zhu J; Yu M; Li M; Lan J; Wang J; Mo X; Wei Y; Niedermann G; Lu Y
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):212-224. PubMed ID: 32417411
[TBL] [Abstract][Full Text] [Related]
23. PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
Smith HG; Mansfield D; Roulstone V; Kyula-Currie JN; McLaughlin M; Patel RR; Bergerhoff KF; Paget JT; Dillon MT; Khan A; Melcher A; Thway K; Harrington KJ; Hayes AJ
Clin Cancer Res; 2019 Jun; 25(11):3443-3454. PubMed ID: 30885937
[TBL] [Abstract][Full Text] [Related]
24. OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.
Lai C; August S; Albibas A; Behar R; Cho SY; Polak ME; Theaker J; MacLeod AS; French RR; Glennie MJ; Al-Shamkhani A; Healy E
Clin Cancer Res; 2016 Aug; 22(16):4236-48. PubMed ID: 27034329
[TBL] [Abstract][Full Text] [Related]
25. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
26. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH
J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566
[TBL] [Abstract][Full Text] [Related]
27. Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.
Lin X; Zeng T; Xiong J; Zhang Q; Jiang P; Li X; Lin S; Xu Q; Weng H; Lai H; Gong H; Lin J; Cheng N; Tian X; Xu Y; Fang S; Jin R; Chen Z; Yang J; Morton L; Yueh B; Lin J
Cancer Biol Ther; 2019; 20(5):666-679. PubMed ID: 30572778
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
Chow MT; Ozga AJ; Servis RL; Frederick DT; Lo JA; Fisher DE; Freeman GJ; Boland GM; Luster AD
Immunity; 2019 Jun; 50(6):1498-1512.e5. PubMed ID: 31097342
[TBL] [Abstract][Full Text] [Related]
29. Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth.
Badeaux MD; Rolig AS; Agnello G; Enzler D; Kasiewicz MJ; Priddy L; Wiggins JF; Muir A; Sullivan MR; Van Cleef J; Daige C; Vander Heiden MG; Rajamanickam V; Wooldridge JE; Redmond WL; Rowlinson SW
Cancer Immunol Res; 2021 Apr; 9(4):415-429. PubMed ID: 33500272
[TBL] [Abstract][Full Text] [Related]
30. Radiation Augments the Local Anti-Tumor Effect of
Pieper AA; Zangl LM; Speigelman DV; Feils AS; Hoefges A; Jagodinsky JC; Felder MA; Tsarovsky NW; Arthur IS; Brown RJ; Birstler J; Le T; Carlson PM; Bates AM; Hank JA; Rakhmilevich AL; Erbe AK; Sondel PM; Patel RB; Morris ZS
Front Immunol; 2021; 12():763888. PubMed ID: 34868010
[TBL] [Abstract][Full Text] [Related]
31. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
[TBL] [Abstract][Full Text] [Related]
32. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
[TBL] [Abstract][Full Text] [Related]
33. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model.
Hu Y; Paris S; Bertolet G; Barsoumian HB; Wang Q; Da Silva J; Patel NB; Nguyen N; Doss DJ; Huang A; Hsu E; Leyton CSK; Voss TA; Masrorpour F; Leuschner C; Pietz JT; Puebla-Osorio N; Gandhi S; Nguyen QN; Wang J; Cortez MA; Welsh JW
Front Immunol; 2022; 13():1022011. PubMed ID: 36405757
[TBL] [Abstract][Full Text] [Related]
34. IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.
Seo H; Kim BS; Bae EA; Min BS; Han YD; Shin SJ; Kang CY
Cancer Immunol Res; 2018 Jun; 6(6):685-695. PubMed ID: 29615398
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Duhen R; Ballesteros-Merino C; Frye AK; Tran E; Rajamanickam V; Chang SC; Koguchi Y; Bifulco CB; Bernard B; Leidner RS; Curti BD; Fox BA; Urba WJ; Bell RB; Weinberg AD
Nat Commun; 2021 Feb; 12(1):1047. PubMed ID: 33594075
[TBL] [Abstract][Full Text] [Related]
37. Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.
Wang X; Waschke BC; Woolaver RA; Chen Z; Zhang G; Piscopio AD; Liu X; Wang JH
Cancer Immunol Res; 2019 Aug; 7(8):1318-1331. PubMed ID: 31235619
[TBL] [Abstract][Full Text] [Related]
38. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.
Barsoumian HB; He K; Hsu E; Bertolet G; Sezen D; Hu Y; Cortez MA; Welsh JW
Res Sq; 2023 Feb; ():. PubMed ID: 36824846
[TBL] [Abstract][Full Text] [Related]
39. Peripheral CX3CR1
Li C; Zhang Z; Cai Q; Zhao Q; Wu H; Li J; Liu Y; Zhao X; Liu J; Ping Y; Shan J; Yang S; Zhang Y
Oncoimmunology; 2024; 13(1):2355684. PubMed ID: 38798746
[TBL] [Abstract][Full Text] [Related]
40. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.
Kim JE; Patel MA; Mangraviti A; Kim ES; Theodros D; Velarde E; Liu A; Sankey EW; Tam A; Xu H; Mathios D; Jackson CM; Harris-Bookman S; Garzon-Muvdi T; Sheu M; Martin AM; Tyler BM; Tran PT; Ye X; Olivi A; Taube JM; Burger PC; Drake CG; Brem H; Pardoll DM; Lim M
Clin Cancer Res; 2017 Jan; 23(1):124-136. PubMed ID: 27358487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
